<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04221269</url>
  </required_header>
  <id_info>
    <org_study_id>1908-001</org_study_id>
    <nct_id>NCT04221269</nct_id>
  </id_info>
  <brief_title>Suicide Prevention Intervention for Schizophrenia-Spectrum Disorders</brief_title>
  <acronym>CLASP-S</acronym>
  <official_title>Post-Hospital Suicide Prevention Intervention for Patients With Schizophrenia-Spectrum Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Butler Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>American Foundation for Suicide Prevention</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Butler Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The current project is a pilot randomized controlled trial to test the Coping Long-term with
      Active Suicide Program for schizophrenia-spectrum disorders (CLASP-S) for patients following
      a psychiatric hospitalization. Participants will be assigned to enhanced treatment as usual
      (ETAU) alone vs CLASP-S plus ETAU. Participants complete assessments at baseline during their
      psychiatric hospitalization and at 3 months (mid-treatment) and 6 months (post-treatment)
      following discharge. The primary aim is to assess the feasibility and acceptability of
      CLASP-S. The secondary aim is to estimate the effects of CLASP-S on reducing suicidal
      thoughts and behaviors relative to ETAU.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 1, 2020</start_date>
  <completion_date type="Anticipated">October 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Client Satisfaction Questionnaire</measure>
    <time_frame>6 months</time_frame>
    <description>The Client Satisfaction Questionnaire is a self-report measure of patient satisfaction with treatment. The total score (sum of items) will be used and ranges from 8 to 32 with increased scores indicating greater satisfaction with treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Columbia Suicide Severity Rating Scale</measure>
    <time_frame>6 months</time_frame>
    <description>The Columbia Suicide Severity Rating Scale is an interviewer-rated measure of suicidal thoughts and behaviors. The total score (sum of items) will be used and ranges from 2 to 25 with higher scores indicating higher suicidal thoughts and behaviors.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Schizophrenia</condition>
  <condition>Suicide</condition>
  <arm_group>
    <arm_group_label>Enhanced Treatment as Usual</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants assigned to Enhanced Treatment as Usual (ETAU) alone will receive unrestricted routine care in the community. Assessment feedback reports will be sent to participants' community providers at baseline, 3 months, and 6 months for care coordination.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Coping Long-term with Active Suicide Program for Schizophrenia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Coping Long-term with Active Suicide Program for Schizophrenia-Spectrum Disorders (CLASP-S) includes 3 individual sessions, 1 family meeting, and 11 phone sessions with the participant and their significant other over 6 months post-hospital discharge.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Enhanced Treatment as Usual</intervention_name>
    <description>Routine community care plus assessment feedback reports to clinicians.</description>
    <arm_group_label>Coping Long-term with Active Suicide Program for Schizophrenia</arm_group_label>
    <arm_group_label>Enhanced Treatment as Usual</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Coping Long-term with Active Suicide Program for Schizophrenia</intervention_name>
    <description>Adjunctive psychosocial intervention for suicide prevention involving in person, family, and phone sessions.</description>
    <arm_group_label>Coping Long-term with Active Suicide Program for Schizophrenia</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  suicidal thoughts or behaviors prior to hospital admission

          -  diagnosis of a schizophrenia-spectrum disorder

          -  receiving pharmacotherapy

          -  18 years or older

          -  speaks/reads English

        Exclusion Criteria:

          -  psychosis due to substance use or medical condition

          -  lack of phone access

          -  discharge to long-term facility
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brandon Gaudiano, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Butler Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Cheryl Cordeira</last_name>
    <phone>401-455-6654</phone>
    <email>CCordeiro@butler.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Butler Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02906</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>January 6, 2020</study_first_submitted>
  <study_first_submitted_qc>January 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 9, 2020</study_first_posted>
  <last_update_submitted>May 1, 2020</last_update_submitted>
  <last_update_submitted_qc>May 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>psychiatric hospitalization</keyword>
  <keyword>suicide prevention</keyword>
  <keyword>psychosis</keyword>
  <keyword>psychosocial intervention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
    <mesh_term>Suicide</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>After all data have been collected and the results of the studies published, de-identified data will be made available to other qualified researchers on request.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

